A Phase 2 interventional study of Alirocumab and Placebo in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 22 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-22.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 27th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 2, and was the 2nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2011, is one of 5 in phase 2, and was the 2nd registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
Inclusion Criteria:
Key Exclusion Criteria:
Use of a medication (other than a statin or EZE) to alter serum lipids within 42 days (6 weeks) before screening including, but not limited to:
Use of nutraceuticals or OTC medications that may alter lipid levels that are not stable for at least 6 weeks before screening and are not planned to remain constant throughout the study. Examples include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
Drug: Placebo
Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
Drug: Alirocumab
Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
Drug: Alirocumab
Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
Drug: Alirocumab
Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
Drug: Alirocumab
Alirocumab two SC injections in the abdomen only.
Also known as: REGN727/SAR236553
Placebo two SC injections in the abdomen only.
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational medicinal product (IMP) injection up to 21 days after last IMP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
Calculated LDL-C value was obtained from Friedewald formula. Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis
Calculated LDL-C value was obtained from Friedewald formula.
Time frame: Week 12 (LOCF)
Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis
Calculated LDL-C value was obtained from Friedewald formula.
Time frame: Week 12 (LOCF)
Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint..
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)
Time frame: From Baseline to Week 12 (LOCF)
Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12
Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)
Time frame: From Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)
Time frame: From Baseline to Week 12 (LOCF)
The study was conducted at 16 centers in the United States of America and Canada. Overall, 118 participants were screened between January 2011 and June 2011.
| Milestone | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Started | 15 | 15 | 16 | 15 | 16 |
| Completed | 15 | 15 | 16 | 14 | 16 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational medicinal product (IMP) injection up to 21 days after last IMP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis | -10.7 ± 5.0 | -28.9 ± 5.1 | -31.5 ± 4.9 | -42.5 ± 5.1 | -67.9 ± 4.9 |
Calculated LDL-C value was obtained from Friedewald formula. Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis | -19.1 ± 7.9 | -42.2 ± 8.0 | -51.3 ± 7.7 | -66.9 ± 8.0 | -102.5 ± 7.6 |
Calculated LDL-C value was obtained from Friedewald formula.
| percentage of participants | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis | 13.3 | 26.7 | 18.8 | 66.7 | 93.8 |
Calculated LDL-C value was obtained from Friedewald formula.
| percentage of participants | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis | 0.0 | 13.3 | 12.5 | 46.7 | 81.3 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis | -8.5 ± 3.8 | -18.1 ± 3.9 | -19.7 ± 3.7 | -25.7 ± 3.8 | -43.6 ± 3.7 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis | -20.3 ± 9.4 | -40.3 ± 9.5 | -50.1 ± 9.2 | -61.7 ± 9.5 | -99.9 ± 9.1 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint..
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis | 2.2 ± 3.7 | 7.9 ± 3.7 | 6.5 ± 3.5 | 1.00 ± 3.8 | 12.3 ± 3.6 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis | 0.4 ± 1.9 | 4.2 ± 1.9 | 3.3 ± 1.8 | 4.5 ± 2.0 | 6.0 ± 1.8 |
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis | -10.6 (-28.5 to 9.5) | -16.7 (-30.1 to 21.1) | -13.2 (-30.9 to 7.4) | -4.9 (-17.0 to 10.3) | -16.2 (-30.7 to 25.1) |
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis | -11.0 (-89.5 to 7.5) | -20.0 (-37.0 to 13.0) | -13.5 (-35.3 to 9.5) | -3.5 (-33.0 to 6.0) | -14.8 (-64.5 to 34.0) |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis | -11.3 ± 4.7 | -26.8 ± 4.8 | -27.4 ± 4.6 | -39.0 ± 4.8 | -57.9 ± 4.6 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis | -22.8 ± 8.8 | -46.0 ± 8.9 | -52.3 ± 8.6 | -70.6 ± 9.0 | -103.6 ± 8.5 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis | -6.4 ± 4.2 | -20.9 ± 4.2 | -20.9 ± 4.0 | -28.4 ± 4.3 | -50.2 ± 4.0 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis | -9.3 ± 5.5 | -24.3 ± 5.5 | -28.7 ± 5.3 | -34.7 ± 5.6 | -64.4 ± 5.3 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis | -5.3 ± 3.1 | 2.4 ± 3.1 | 1.7 ± 2.9 | 5.6 ± 3.1 | 8.8 ± 2.9 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis | -9.7 ± 4.6 | 3.4 ± 4.5 | 2.8 ± 4.3 | 7.8 ± 4.6 | 11.0 ± 4.4 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| ratio | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis | -0.03 ± 0.04 | -0.18 ± 0.04 | -0.20 ± 0.04 | -0.25 ± 0.04 | -0.49 ± 0.04 |
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)
| percent change | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis | -3.9 (-18.4 to 0.0) | -10.1 (-22.2 to 3.8) | -7.5 (-22.5 to 0.0) | -15.3 (-25.2 to 10.6) | -23.4 (-44.6 to -6.6) |
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)
| mg/dL | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis | -2.0 (-7.0 to 0.0) | -1.5 (-10.0 to 1.5) | -1.8 (-5.0 to 0.0) | -8.0 (-19.0 to 5.0) | -11.5 (-26.0 to 1.8) |
Collected over From Baseline up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/15 (6.7%) | 9/15 (60%) |
| Alirocumab 150 mg Q4W | — | 0/15 (0%) | 12/15 (80%) |
| Alirocumab 200 mg Q4W | — | 0/16 (0%) | 13/16 (81.3%) |
| Alirocumab 300 mg Q4W | — | 0/15 (0%) | 13/15 (86.7%) |
| Alirocumab 150 mg Q2W | — | 0/16 (0%) | 12/16 (75%) |
| Event | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 1/15 | 0/15 | 0/16 | 0/15 | 0/16 |
| Event | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/15 | 2/15 | 4/16 | 4/15 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 3/15 | 3/16 | 1/15 | 0/16 |
| Injection site haematomaGeneral disorders | 1/15 | 3/15 | 0/16 | 2/15 | 1/16 |
| Injection site pruritusGeneral disorders | 0/15 | 0/15 | 0/16 | 3/15 | 0/16 |
| FatigueGeneral disorders | 1/15 | 2/15 | 1/16 | 2/15 | 0/16 |
| Injection site exfoliationGeneral disorders | 0/15 | 0/15 | 1/16 | 2/15 | 0/16 |
| NasopharyngitisInfections and infestations | 2/15 | 0/15 | 2/16 | 1/15 | 0/16 |
| SinusitisInfections and infestations | 0/15 | 2/15 | 0/16 | 1/15 | 0/16 |
| Upper respiratory tract infectionInfections and infestations | 0/15 | 0/15 | 0/16 | 2/15 | 0/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/15 | 2/15 | 0/16 | 1/15 | 0/16 |
| Age, Continuous(years) | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|---|
| Mean | 51.9 ± 9.6 | 51.3 ± 7.7 | 52.9 ± 11.2 | 54.3 ± 9.6 | 56.3 ± 10.2 | 53.4 ± 9.7 |
| Sex: Female, Male(Participants) | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 6 | 7 | 8 | 3 | 30 |
| Male | 9 | 9 | 9 | 7 | 13 | 47 |
| Low Density Lipoprotein Cholesterol (LDL-C) in mg/dL(mg/dL) | Placebo | Alirocumab 150 mg Q4W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|---|
| Mean | 150.8 ± 34.0 | 166.7 ± 50.1 | 169.8 ± 57.0 | 139.6 ± 24.7 | 147.2 ± 32.6 | 154.9 ± 42.1 |
The record gives a start of Jan 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 3 years 10 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab